NCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
Clinical Trials
57 trialsNCT05903092 2026-03-12
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
NCT05068232 2026-03-04
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
Phase 2 Recruiting
NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
NCT05223647 2026-01-28
TRIPLEX
Norwegian University of Science and Technology
Phase 3 Terminated
NCT04472949 2025-10-01
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT06838208 2025-09-24
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT05796089 2025-08-26
CHEST RT
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT06951841 2025-04-30
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 4 Not yet recruiting
NCT06931145 2025-04-23
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06717243 2025-03-19
STRATUS
Oncology Center of Biochemical Education And Research
Recruiting
NCT06869239 2025-03-11
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Peking University Cancer Hospital & Institute
Recruiting
NCT06769971 2025-01-10
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Sichuan University
Phase 2 Recruiting
NCT06480864 2025-01-06
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
China Medical University, China
Phase NA Recruiting
NCT04923776 2024-12-30
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Columbia University
Phase 2 Terminated
NCT06732258 2024-12-27
Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Not yet recruiting
NCT04951115 2024-11-26
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT06698965 2024-11-21
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital
Phase 2 Recruiting
NCT00686985 2024-09-20
DOCAR
Jeroen Bosch Ziekenhuis
Phase 2 Completed
NCT06536868 2024-08-05
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Second Hospital of Shanxi Medical University
Phase 2 Recruiting
NCT06295926 2024-07-22
Serplulimab Combined With CCRT for LS-SCLC.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06497530 2024-07-12
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Not yet recruiting
NCT04730999 2024-07-05
CeLEBrATE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT04562337 2024-07-03
SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
Shandong Cancer Hospital and Institute
Phase 2 Active not recruiting
NCT05765825 2024-06-20
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
Sichuan University
Phase 2 Recruiting
NCT06375109 2024-04-19
NeoSCLC-001
Beijing Chest Hospital, Capital Medical University
Phase 2 Not yet recruiting
NCT04487756 2024-04-03
VENEZO-LUNG
Instituto Oncológico Dr Rosell
Phase 1/2 Active not recruiting
NCT04610684 2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT06306560 2024-03-12
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
Harbin Medical University
Phase 2 Not yet recruiting
NCT05957510 2024-02-22
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
NCT03913455 2023-12-20
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT06177925 2023-12-20
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT03963414 2023-08-28
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
University of Nebraska
Phase 1 Terminated
NCT04539977 2023-05-09
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT05484583 2022-08-05
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT00695292 2021-11-22
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02934503 2021-11-16
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NYU Langone Health
Phase 2 Terminated
NCT03059667 2021-02-10
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT04731909 2021-02-10
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
Third Military Medical University
Phase NA Unknown
NCT04696939 2021-01-06
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04363255 2020-04-28
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Taizhou Hospital
Phase 2 Unknown
NCT00702962 2018-10-22
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT00387660 2018-01-10
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
University of California, Davis
Phase 2 Completed
NCT00807755 2018-01-09
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
University of California, Davis
Phase 1 Terminated
NCT00717938 2017-08-25
RASTEN
Lund University Hospital
Phase 3 Completed
NCT00856830 2017-07-17
Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00454324 2017-07-11
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00958022 2017-06-22
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
University of Pittsburgh
Phase 1 Terminated